PT - JOURNAL ARTICLE AU - Chadwick, David R AU - Barker, Fred AU - Smith, Colette AU - Perditer, Okyere AU - Hardy, Yasmine AU - Owusu, Dorcas AU - Villa, Giovanni AU - Sarfo, Fred Stephen AU - Geretti, Anna-Maria AU - Phillips, Richard TI - Predictors of long-term progression to chronic kidney disease in HIV infection in Ghana from 2003-2018 AID - 10.1101/2022.11.23.22282665 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.23.22282665 4099 - http://medrxiv.org/content/early/2022/11/24/2022.11.23.22282665.short 4100 - http://medrxiv.org/content/early/2022/11/24/2022.11.23.22282665.full AB - Aim HIV is associated with an increased risk of progression to chronic kidney disease (CKD), and this risk is higher in people of West African descent than many other ethnicities. Our study aimed to assess the rates of progression to CKD and predictors of rapid progression in patients receiving antiretroviral therapy (ART) in central Ghana between 2003 and 2018.Methods This single-centre retrospective study enrolled people with HIV (PWH) initiating ART in Ghana between 2003-2018. Demographics, hepatitis B (HBsAg) status, ART regimens and eGFR measurements were recorded, and multi-level model linear regression was performed to determine predictors of greater levels of eGFR decline.Results 659 participants were included in the study with a median follow-up time of 6 years (IQR 3.6-8.9). 149 participants (22.6%) also had confirmed HBV co-infection. Tenofovir was associated with the highest mean rate of eGFR decline of all Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), representing a statistically significant annual decline -1.08 mL/min/1.73m2/year (CI: -0.24, -1.92) faster than those taking zidovudine. Regarding other ARTs, both nevirapine (-0.78mL /min/173m2/year; CI: -0.17, -1.39) and protease inhibitors (-1.55mL/mil/173m2/year; CI: - 0.41, -2.68) were associated with slower eGFR declines compared with efavirenz. Negative HbsAg status was associated with greater eGFR decline compared with positive HBsAg status (-1.25mL/mil/173m2; CI 0.29. 2.20).Conclusion Increased rates of eGFR decline amongst PWH in Ghana were associated with tenofovir, nevirapine, and protease inhibitor use as well as negative HBsAg status. Further higher-quality research is needed to explore long-term predictors of eGFR decline in African populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNO - The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee on Human Research Publications and Ethics at Kwame Nkrumah University of Science and Technology (KNUST) approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData can be accessed through emailing corresponding author and can be made publicly accessible if necessaryHIVHuman immunodeficiency virusPWHPeople living with HIVHIVANHIV-associated nephropathyARTAntiretroviral therapyESRDEnd stage renal diseaseHBVHepatitis B virus